So far, β-blockers, ACE inhibitors, and ARBs have been the most commonly evaluated antihypertensive agents in the context of cancer, while thiazide and thiazide-like diuretics have been less studied (Carlos-Escalante et al., 2021). The gene discussed is ACE; the disease is cancer.